VivoSeq
Neurology

Focal Epilepsy

2

Pipeline Programs↗

3

Active Trials↗

3

Companies Involved↗

Focal Epilepsy is an early-stage landscape with 2 programs across 3 companies. The most active players are Xenon Pharmaceuticals Inc., Biohaven Therapeutics Ltd., Eli Lilly. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

X

Xenon Pharmaceuticals Inc.

1 program

Phase 3B

Biohaven Therapeutics Ltd.

1 program

PreclinicalEli Lilly logo

Eli Lilly

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical1

BHV-7000

Biohaven Therapeutics Ltd.

Phase 1
No programs
Phase 2
No programs
Phase 31

XEN1101

Xenon Pharmaceuticals Inc.

Approved
No programs

Analysis

Trial Status

4

clinical trials

Recruiting1 · 25%
Enrolling by invitation1 · 25%
Completed1 · 25%
Active, not recruiting1 · 25%

Clinical Trials

Trial Activity

Precision Resection of the Epileptogenic Zone Using Intraoperative Submillimeter Micro-Electrocorticography (Epi-PRECISE): A Single-Arm Trial With an External Historical Control Cohort
Recruiting·BBeijing Tiantan Hospital·Preclinical·NCT07656857·85 enrolled
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy
Enrolling by invitation·XXenon Pharmaceuticals Inc.·Phase 3·NCT05718817·880 enrolled
Slow Oscillatory Transcranial Direct Current Stimulation for Treating Refractory Focal Epilepsy
Completed·TThe First Hospital of Hebei Medical University·Preclinical·NCT07684352·10 enrolled
A Phase 2/3 Multicenter, Randomization, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy
Active, not recruiting·BBiohaven Therapeutics Ltd.·Preclinical·NCT06309966·390 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)